Maraviroc: pharmacokinetics and drug interactionsABE, Samantha; BACK, David J; VOURVAHIS, Manoli et al.Antiviral therapy (London). 2009, Vol 14, Num 5, pp 607-618, issn 1359-6535, 12 p.Article

The implications of P-glycoprotein in HIV : friend or foe?OWEN, Andrew; CHANDLER, Becky; BACK, David J et al.Fundamental & clinical pharmacology. 2005, Vol 19, Num 3, pp 283-296, issn 0767-3981, 14 p.Article

The role of clinical pharmacology in optimizing antiretroviral therapyBACK, David J; KHOO, Saye H.British journal of clinical pharmacology. 2003, Vol 55, Num 5, pp 473-476, issn 0306-5251, 4 p.Article

Pharmacogenetics of HIV therapyOWEN, Andrew; PIRMOHAMED, Munir; KHOO, Saye H et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 10, pp 693-703, issn 1744-6872, 11 p.Article

Therapeutic drug monitoring as a tool in treating HIV infectionKHOO, Saye H; GIBBONS, Sara E; BACK, David J et al.AIDS (Supplement). 2001, Vol 15, pp S171-S181, issn 1350-2840, SUP5Article

IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ PatientsLIPTROTT, Neill J; EGAN, Deirdre; BACK, David J et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 5, pp 442-445, issn 1525-4135, 4 p.Article

Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitorsJONES, Simon P; JANNEH, Omar; BACK, David J et al.Antiviral therapy (London). 2005, Vol 10, Num 2, pp 207-213, issn 1359-6535, 7 p.Article

Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approachLAMORDE, Mohammed; SCHAPIRO, Jonathan M; BURGER, David et al.AIDS (London). 2014, Vol 28, Num 17, pp 2551-2563, issn 0269-9370, 13 p.Article

Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and RifapentineWILLIAMSON, Beth; DOOLEY, Kelly E; YUAN ZHANG et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 12, pp 6366-6369, issn 0066-4804, 4 p.Article

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytesJANNEH, Omar; BRAY, Patrick G; JONES, Elizabeth et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 5, pp 906-916, issn 0305-7453, 11 p.Article

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individualsDICKINSON, Laura; BOFFITO, Marta; BACK, David J et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 62, Num 6, pp 1344-1355, issn 0305-7453, 12 p.Article

A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicinHARTKOORN, Ruben C; WOO, Saye; BACK, David J et al.Journal of chromatography. B. 2007, Vol 857, Num 1, pp 76-82, issn 1570-0232, 7 p.Article

The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors : Implications for once-daily dosingBACK, David J; BURGER, David M; FLEXNER, Charles W et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 39, pp S1-S23, issn 1525-4135, SUP1Article

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoringBOFFITO, Marta; BACK, David J; HOGGARD, Patrick G et al.AIDS (London). 2003, Vol 17, Num 7, pp 1107-1108, issn 0269-9370, 2 p.Article

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamicsBOFFITO, Marta; ARNAUDO, Isabella; RAITERI, Riccardo et al.AIDS (London). 2002, Vol 16, Num 15, pp 2081-2083, issn 0269-9370, 3 p.Article

Simultaneous determination of rifampicin and efavirenz in plasmaBOFFITO, Marta; TIJA, John; REYNOLDS, Helen E et al.Therapeutic drug monitoring. 2002, Vol 24, Num 5, pp 670-674, issn 0163-4356, 5 p.Article

Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavirHOLLADAY, John W; DEWEY, Michael J; MICHNIAK, Bozena B et al.Drug metabolism and disposition. 2001, Vol 29, Num 3, pp 299-303, issn 0090-9556Article

The role of therapeutic drug monitoring in treatment of HIV infectionBACK, David J; KHOO, Saye H; GIBBONS, Sara E et al.British journal of clinical pharmacology. 2001, Vol 51, Num 4, pp 301-308, issn 0306-5251Conference Paper

Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatmentLAMORDE, Mohammed; BYAKIKA-KIBWIKA, Pauline; MAYITO, Jonathan et al.AIDS (London). 2013, Vol 27, Num 6, pp 961-965, issn 0269-9370, 5 p.Article

Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In VitroMOSS, Darren M; LIPTROTT, Neill J; CURLEY, Paul et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 11, pp 5612-5618, issn 0066-4804, 7 p.Article

Divalent Metals and pH Alter Raltegravir Disposition In VitroMOSS, Darren M; SICCARDI, Marco; MURPHY, Matthew et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3020-3026, issn 0066-4804, 7 p.Article

Adipogenic gene variants in patients with HIV-associated lipodystrophyPUSHPAKOM, Sudeep P; OWEN, Andrew; JAVIER VILAR, F et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 2, pp 76-83, issn 1744-6872, 8 p.Article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsHARTKOORN, Ruben C; WAI SAN KWAN; BACK, David J et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 2, pp 112-120, issn 1744-6872, 9 p.Article

Effect of transporter modulation on the emergence of nelfinavir resistance in vitroCHANDLER, Becky; DETSIKA, Maria; OWEN, Andrew et al.Antiviral therapy (London). 2007, Vol 12, Num 5, pp 831-834, issn 1359-6535, 4 p.Article

Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytesJANNEH, Omar; HOGGARD, Patrick G; TJIA, John F et al.Antiviral therapy (London). 2003, Vol 8, Num 5, pp 417-426, issn 1359-6535, 10 p.Article